<?xml version="1.0" encoding="UTF-8"?><mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="id-E7-5740">
    <name type="corporate">
        <namePart>United States Government Publishing Office</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
            <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
        </role>
        <role>
            <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
            <roleTerm authority="marcrelator" type="code">dst</roleTerm>
        </role>
    </name>
    <name type="corporate">
        <namePart>United States</namePart>
        <namePart>National Archives and Records Administration</namePart>
        <namePart>Office of the Federal Register</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">author</roleTerm>
            <roleTerm authority="marcrelator" type="code">aut</roleTerm>
        </role>
        <description>Government Organization</description>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="marcgt">government publication</genre>
    <language>
        <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <extension>
        <collectionCode>FR</collectionCode>
        <category>Regulatory Information</category>
        <waisDatabaseName>2007_register</waisDatabaseName>
        <branch>executive</branch>
        <dateIngested>2010-09-22</dateIngested>
    </extension>
    <genre authority="marcgt">article</genre>
    <titleInfo>
        <title>Laxative Drug Products for Over-the-Counter Human Use; Psyllium Ingredients in Granular Dosage Forms</title>
        <partName>Rules and Regulations</partName>
    </titleInfo>
    <relatedItem type="otherFormat" xlink:href="https://www.govinfo.gov/content/pkg/FR-2007-03-29/html/E7-5740.htm">
        <identifier type="FDsys Unique ID">D09002ee1c80b3260</identifier>
    </relatedItem>
    <relatedItem type="otherFormat" xlink:href="https://www.govinfo.gov/content/pkg/FR-2007-03-29/pdf/E7-5740.pdf">
        <identifier type="FDsys Unique ID">D09002ee1c80b3301</identifier>
    </relatedItem>
    <name type="corporate">
        <namePart>United States</namePart>
        <namePart>Department of Health and Human Services</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">originator</roleTerm>
            <roleTerm authority="marcrelator" type="code">org</roleTerm>
        </role>
        <description>United States Government Agency or Subagency</description>
    </name>
    <name type="corporate">
        <namePart>United States</namePart>
        <namePart>Food and Drug Administration</namePart>
        <role>
            <roleTerm authority="marcrelator" type="text">originator</roleTerm>
            <roleTerm authority="marcrelator" type="code">org</roleTerm>
        </role>
        <description>United States Government Agency or Subagency</description>
    </name>
    <abstract>The Food and Drug Administration (FDA) is issuing a final rule establishing that over-the-counter (OTC) laxative drug products in granular dosage form containing the bulk-forming psyllium ingredients (psyllium (hemicellulose), psyllium hydrophilic mucilloid, psyllium seed, psyllium seed (blond), psyllium seed husks, plantago ovata husks, and plantago seed) are not generally recognized as safe and effective (GRASE) and are misbranded. This final rule includes, but is not limited to, any granules that are swallowed dry prior to drinking liquid; dispersed, suspended, or partially dissolved in liquid prior to swallowing; chewed, partially chewed, or unchewed, and then washed down (or swallowed) with liquid; or sprinkled over food. FDA is issuing this final rule after considering reports of esophageal obstruction associated with the use of psyllium laxatives in granular dosage form. These cases continue to occur despite efforts to promote safe use through label warnings and directions. This final rule does not apply to psyllium laxatives in nongranular dosage forms, such as powders, tablets, or wafers. This final rule is part of FDA's ongoing review of OTC drug products.</abstract>
    <identifier type="FR citation">72 FR 14669</identifier>
    <identifier type="uri">https://www.govinfo.gov/app/details/FR-2007-03-29/E7-5740</identifier>
    <identifier type="FR Doc No.">E7-5740</identifier>
    <identifier type="former granule identifier">fr29mr07-8</identifier>
    <identifier type="Regulation ID Number">RIN 0910-AF38</identifier>
    <identifier type="billing code">4160-01-S</identifier>
    <identifier type="department code">Docket No. 1978N-0036L</identifier>
    <location>
        <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/FR-2007-03-29/E7-5740</url>
        <url access="raw object" displayLabel="HTML rendition">https://www.govinfo.gov/content/pkg/FR-2007-03-29/html/E7-5740.htm</url>
        <url access="raw object" displayLabel="PDF rendition">https://www.govinfo.gov/content/pkg/FR-2007-03-29/pdf/E7-5740.pdf</url>
    </location>
    <physicalDescription>
        <extent>6 p.</extent>
    </physicalDescription>
    <part type="Rules and Regulations">
        <extent unit="pages">
            <start>14669</start>
            <end>14674</end>
        </extent>
    </part>
    <identifier type="preferred citation">72 FR 14669</identifier>
    <relatedItem type="isReferencedBy">
        <titleInfo>
            <title>Code of Federal Regulations</title>
            <partNumber>Title 21 Part 201</partNumber>
        </titleInfo>
        <identifier type="CFR citation">21 CFR Part  201</identifier>
    </relatedItem>
    <relatedItem type="isReferencedBy">
        <titleInfo>
            <title>Code of Federal Regulations</title>
            <partNumber>Title 21 Part 310</partNumber>
        </titleInfo>
        <identifier type="CFR citation">21 CFR Part  310</identifier>
    </relatedItem>
    <relatedItem type="isReferencedBy">
        <titleInfo>
            <title>Regulation Identification Number 0910-AF38</title>
        </titleInfo>
        <identifier type="regulation ID number">RIN 0910-AF38</identifier>
    </relatedItem>
    <extension>
        <searchTitle>Laxative Drug Products for Over-the-Counter Human Use; Psyllium Ingredients in Granular Dosage Forms; Federal Register Vol. 72, Issue </searchTitle>
        <granuleClass>RULE</granuleClass>
        <accessId>E7-5740</accessId>
        <agency order="1">DEPARTMENT OF HEALTH AND HUMAN SERVICES</agency>
        <agency order="2">Food and Drug Administration</agency>
        <effectiveDate>2007-10-01</effectiveDate>
        <departmentDoc>Docket No. 1978N-0036L</departmentDoc>
        <rin number="0910-AF38"/>
        <billingCode>4160-01-S</billingCode>
        <frDocNumber>E7-5740</frDocNumber>
        <action>Final rule.</action>
        <summary>The Food and Drug Administration (FDA) is issuing a final rule establishing that over-the-counter (OTC) laxative drug products in granular dosage form containing the bulk-forming psyllium ingredients (psyllium (hemicellulose), psyllium hydrophilic mucilloid, psyllium seed, psyllium seed (blond), psyllium seed husks, plantago ovata husks, and plantago seed) are not generally recognized as safe and effective (GRASE) and are misbranded. This final rule includes, but is not limited to, any granules that are swallowed dry prior to drinking liquid; dispersed, suspended, or partially dissolved in liquid prior to swallowing; chewed, partially chewed, or unchewed, and then washed down (or swallowed) with liquid; or sprinkled over food. FDA is issuing this final rule after considering reports of esophageal obstruction associated with the use of psyllium laxatives in granular dosage form. These cases continue to occur despite efforts to promote safe use through label warnings and directions. This final rule does not apply to psyllium laxatives in nongranular dosage forms, such as powders, tablets, or wafers. This final rule is part of FDA's ongoing review of OTC drug products.</summary>
        <dates>Effective Date: This rule is effective October 1, 2007.</dates>
        <contact>Reynold Tan, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, MS 5411, Silver Spring, MD 20993-0002, 301- 796-2090.</contact>
        <cfr title="21">
                                    
            <part number="201"/>
                                
        </cfr>
        <cfr title="21">
                                    
            <part number="310"/>
                                
        </cfr>
        <urlRef>http://www.fda.gov/ohrms/dockets/default.htm</urlRef>
    </extension>
    <relatedItem type="host" ID="P0b002ee180965bdb" xlink:href="https://www.govinfo.gov/metadata/pkg/FR-2007-03-29/mods.xml">
        <titleInfo>
            <title>Federal Register</title>
            <partNumber>Vol. 72, no. 60</partNumber>
        </titleInfo>
        <originInfo>
            <publisher>Office of the Federal Register, National Archives and Records Administration</publisher>
            <dateIssued encoding="w3cdtf">2007-03-29</dateIssued>
            <issuance>continuing</issuance>
            <frequency>daily</frequency>
        </originInfo>
        <physicalDescription>
            <note type="source content type">deposited</note>
            <digitalOrigin>born digital</digitalOrigin>
            <extent>372 p.</extent>
        </physicalDescription>
        <tableOfContents xlink:href="https://www.govinfo.gov/app/frtoc/2007-03-29">    
		  Table of Contents: 
		</tableOfContents>
        <classification authority="sudocs">AE 2.7:</classification>
        <classification authority="sudocs">GS 4.107:</classification>
        <classification authority="sudocs">AE 2.106:</classification>
        <classification authority="lcc">KF70.A2</classification>
        <identifier type="uri">https://www.govinfo.gov/app/details/FR-2007-03-29</identifier>
        <identifier type="local">P0b002ee180965bdb</identifier>
        <identifier type="issn">0097-6326</identifier>
        <identifier type="issn">0042-1219</identifier>
        <identifier type="issn">0364-1406</identifier>
        <identifier type="stock number">769-004-00000-9</identifier>
        <identifier type="ILS system id">000582072</identifier>
        <identifier type="former identifier">f:fr29mr07</identifier>
        <location>
            <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/FR-2007-03-29</url>
            <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/FR-2007-03-29/pdf/FR-2007-03-29.pdf</url>
            <url displayLabel="XML rendition" access="raw object">https://www.govinfo.gov/content/pkg/FR-2007-03-29/xml/FR-2007-03-29.xml</url>
        </location>
        <accessCondition type="GPO scope determination">fdlp</accessCondition>
        <part type="issue">
            <extent unit="pages">
                <start>14649</start>
                <end>15008</end>
            </extent>
        </part>
        <recordInfo>
            <recordContentSource authority="marcorg">DGPO</recordContentSource>
            <recordCreationDate encoding="w3cdtf">2010-09-22</recordCreationDate>
            <recordChangeDate encoding="w3cdtf">2024-06-05</recordChangeDate>
            <recordIdentifier source="DGPO">FR-2007-03-29</recordIdentifier>
            <recordOrigin>machine generated</recordOrigin>
            <languageOfCataloging>
                <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
            </languageOfCataloging>
        </recordInfo>
        <extension>
            <docClass>FR</docClass>
            <accessId>FR-2007-03-29</accessId>
            <volume>72</volume>
            <issue>60</issue>
        </extension>
    </relatedItem>
</mods>
